Patient-centric Drug Design and Innovative Technologies Symposium Announced by Catalent Applied Drug Delivery Institute

Share Article

The Catalent Applied Drug Delivery Institute today announced that it will host a symposium entitled “Advanced Drug Delivery Applications: Overcoming Bioavailability Challenges, Patient-Centric Drug Design & Innovative Technologies”, on Tuesday, September 17th, 2015, at the University of Tokyo, Sanjo Kaikan, Japan.

This is the first event that we have hosted in Japan and underlines the truly global nature of the Institute, linking research and industry from all over the world, with the aim of sharing expertise and ideas,” Cornell Stamoran

The Catalent Applied Drug Delivery Institute today announced that it will host a symposium entitled “Advanced Drug Delivery Applications: Overcoming Bioavailability Challenges, Patient-Centric Drug Design & Innovative Technologies”, on Tuesday, September 17th, 2015, at the University of Tokyo, Sanjo Kaikan, Japan.

The event will see world-leading experts on drug development and delivery from across industry and academia, including Okada DDS Research Institute, Catalent Pharma Solutions, BASF Japan, Colorcon Inc., Qualicaps, Okayama University, Daiichi-Sankyo and Hovione, presenting on a number of key industry topics, including patient-centered drug design, drug delivery design and devices, holt melt extrusion, micronization, antibody-drug conjugates, and overcoming limited bioavailability.

The symposium will be co-chaired by Professor Emeritas Hiroaki Okada, from the University of Tokyo School of Pharmacy and Life Sciences, and Tadahiro Matsumura, President of Catalent Japan.

“This is the first event that we have hosted in Japan and underlines the truly global nature of the Institute, linking research and industry from all over the world, with the aim of sharing expertise and ideas,” commented Dr. Cornell Stamoran, Director of the Catalent Applied Drug Delivery Institute. “There are common goals we all share in the wish to improve the patient experience, and bringing novel therapeutics to the market faster. Sharing perspectives and issues concerning not only the wider industry, as well as addressing regional need, is important as we and our partners continue to pursue the Institute’s goals.”

Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies through industry and academic collaboration, research, education, and the sharing of information. In June 2014, the Institute created the Non-Invasive Macromolecule Delivery Consortium (NMDC) as a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics.

The Drug Delivery Institute continues to encourage and promote collaboration in various areas of drug delivery and from 18th to 21st February, 2016, will host the Non-Invasive Delivery of Macromolecules Conference 2016 at the Omni La Costa Resort & Spa, Carlsbad, San Diego, USA. The goal of the meeting is to provide an open and creative forum for academic and industrial scientists to discuss the spectrum of activities, from concept to clinical testing, required for successful development of clinical products.

For more details on the Catalent Institute, visit http://www.drugdeliveryinstitute.com and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent Applied Drug Delivery Institute
Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments and foster industry collaboration on major issues pertaining to drug development, formulation and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website